Considering the significant discrimination of MYCMI-7 between MYCN-amplified and nonamplified neuroblastoma and between the NCI-60 cancer cell lines with “high” versus “low” MYC expression, we anticipate that both MYC amplification and elevated MYC expression, can be used as biomarkers for identification of patients with cancer likely to benefit from MYC inhibitor treatment. The gene discussed is MYCN; the disease is cancer.